PDE4A and chronic obstructive pulmonary disease: Three small-molecule PDE4 inhibitors are currently approved and marketed for the treatment of human diseases: Roflumilast for chronic obstructive pulmonary disease (COPD), crisaborole for atopic dermatitis and Apremilast for psoriatic arthritis [7].